X4 Pharmaceuticals
XFOR
35 hedge funds and large institutions have $45.5M invested in X4 Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 3 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.02% less ownership
Funds ownership: 0.42% → 0.4% (-0.02%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
85% less capital invested
Capital invested by funds: $296M → $45.5M (-$251M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.23M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.83M |
| 3 |
BlackRock
New York
|
+$868K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$331K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$219K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.94M |
| 2 |
JP Morgan Chase
New York
|
-$3.19M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.63M |
| 4 |
Charles Schwab
San Francisco,
California
|
-$200K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$91.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $9K | +$9.82K | +3 | +27% |
|
|
CHP
27
Cable Hill Partners
Portland,
Oregon
| $7K | +$16.4K | +5 | +83% |
|
|
SO
28
STRS Ohio
Columbus,
Ohio
| $4K | – | – | – |
|
29
Barclays
London,
United Kingdom
| $3K | – | – | – |
|
30
Legal & General Group
London,
United Kingdom
| $3K | – | – | – |
|
31
Bank of America
Charlotte,
North Carolina
| $3K | +$9.82K | +3 | +150% |
|
32
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2K | – | – | – |
|
33
Citigroup
New York
| $2K | +$3.27K | +1 | +33% |
|
|
AIP
34
Ameritas Investment Partners
Lincoln,
Nebraska
| $1K | – | – | – |
|
35
BNP Paribas Financial Markets
Paris,
France
| $530 | -$9.82K | -3 | -75% |
|
|
SFM
36
Sphera Funds Management
Tel Aviv,
Israel
| – | -$2.63M | -639 | Closed |
|
|
37
Charles Schwab
San Francisco,
California
| – | -$200K | -48 | Closed |
|
|
KF
38
Krilogy Financial
St. Louis,
Missouri
| – | -$5K | -1 | Closed |
|
XFOR Hedge Fund Activity: Q2 2018 in Review
35 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2018, worth a combined $45.5M — down 85% from $296M a quarter earlier.
Fund positioning in XFOR was balanced in Q2 2018: 3 funds opened new positions, 3 closed out, 12 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.23M. The largest seller was Fidelity Investments, cutting an estimated $7.94M.
- 35 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $45.5M of X4 Pharmaceuticals stock for Q2 2018, down 85% quarter-over-quarter.
- 3 funds opened new X4 Pharmaceuticals positions in Q2 2018 and 3 closed out, a net change of 0 holders.
- The largest X4 Pharmaceuticals buyer in Q2 2018 was Vanguard Group, an estimated $2.23M added.
- The largest X4 Pharmaceuticals seller in Q2 2018 was Fidelity Investments, an estimated $7.94M sold.
Based on aggregated 13F filings for Q2 2018.